---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001326"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:36:13.086934+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart CEO resigns; receives $9.27M U.S. contract for oral XBB vaccine trial

## Summary
- CEO Andrei Floroiu resigns as President, CEO, and board member effective Jan 15, 2024.
- Board Chair Michael J. Finney appointed Interim CEO; receives $595k base salary, 50% bonus target.
- Company awarded $9.27M U.S. govt. contract (ASPR) for planning Phase 2b trial of oral XBB vaccine vs. mRNA.
- Dr. David Wheadon appointed Lead Director with $25k annual retainer.

## SEC filing metadata
- accession: 0001437749-24-001326
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/vxrt20240115_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001326
- JSON: https://secwatch.observer/filing/0001437749-24-001326.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001326.txt

## Key facts
- Executive change
  Andrei Floroiu resigned as President, Chief Executive Officer and Member of the Board of Directors at Vaxart, Inc..
  - Action: resigned
  - Role: President, Chief Executive Officer and Member of the Board of Directors
  source text: On January 15, 2024 (the “Separation Date”), Andrei Floroiu resigned (i) as President and Chief Executive Officer of the Company, and (ii) as a member of the Company’s Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm
- Executive change
  David Wheadon was appointed as Lead Director at Vaxart, Inc..
  - Action: appointed
  - Role: Lead Director
  source text: On January 15, 2024 David Wheadon, M.D. was appointed to serve as Lead Director of the Board and will receive an annual cash retainer equal to $25,000 for such service
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm
- Executive change
  Michael J. Finney was appointed as Interim Chief Executive Officer at Vaxart, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On January 16, 2024, the Board announced that, effective as of January 16, 2024, the current Chair of the Board, Michael J. Finney, Ph.D, has been appointed as Interim Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm
- Material Agreements
  Vaxart, Inc. entered into ASPR Contract with U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR") valued at $9,271,193.00 (effective 2024-01-12).
  - Action: entry
  - Counterparty: U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR")
  - Value: $9,271,193.00
  - Effective: 2024-01-12
  source text: On January 12, 2024, Vaxart, Inc. (the “Company”) was awarded a contract (the “ASPR Contract”) by the U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the “ASPR”). Under the ASPR Contract, the Company will receive an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company’s XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events.
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.